Arylpiperazines having activity at the serotonin 1A receptor
AssigneesAvera Pharmaceuticals, Inc., Eli Lilly and Company
InventorsAlexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
Life of this patent
Estimating the term…
Abstract
A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
Claims12
A method for treating memory loss, the method comprising administering to a patient in need of such treatment of an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating memory loss, the method comprising administering to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating dementia of aging, the method comprising administering to a patient in need of such treatment of an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating dementia of aging, the method comprising administering to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating cognitive disorders, the method comprising administering to a patient in need of such treatment of an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating cognitive disorders, the method comprising administering to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating psychosis, the method comprising administering to a patient in need of such treatment of an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating psychosis, the method comprising administering to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating Alzheimer's diesease, the method comprising administering to a patient in need of such treatment of an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating Alzheimer's diesease, the method comprising administering to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating schizophrenia, the method comprising administering to a patient in need of such treatment of an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
A method for treating schizophrenia, the method comprising administering to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or a pharmaceutically acceptable salt, racemate, or optical isomer thereof.
Dependencies are inferred from the claim text.